Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - kylling - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

intervet international b.v. - live attenuated canine distemper virus strain onderstepoort: 105.1 – 106.5 tcid50, live recombinant canine parvovirus strain 630a: 105.1 – 106.7 tcid50 - immunologicals for canidae - dogs (small) - for the active immunisation of puppies from 4 weeks of age onwards to prevent clinical signs and mortality of canine distemper virus infection and canine parvovirus infection and to prevent viral excretion following canine distemper virus infection and following canine parvovirus infection.

Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaksiner - active immunisation against h5 subtype of influenza a virus.

Norvegia - norvegiană - Statens legemiddelverk

orifarm as - svineparvovirus, inaktivert / erysipelothrix rhusiopathiae, serotype 2, inaktivert - injeksjonsvæske, suspensjon

Norvegia - norvegiană - Statens legemiddelverk

ceva santé animale - svineparvovirus, inaktivert / erysipelothrix rhusiopathiae, serotype 2, inaktivert - injeksjonsvæske, suspensjon

Norvegia - norvegiană - Statens legemiddelverk

orifarm as - svineparvovirus, inaktivert / erysipelothrix rhusiopathiae, serotype 2, inaktivert - injeksjonsvæske, suspensjon

Norvegia - norvegiană - Statens legemiddelverk

bioveta, a. s. - svineparvovirus, inaktivert / erysipelothrix rhusiopathiae, serotype 2, inaktivert - injeksjonsvæske, suspensjon

Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - svin parvovirus, belastning 27a, viral protein 2 - immunologicals for suidae - griser - for aktive vaksinering av statsobligasjoner og sår fra fylte 5 måneder for å beskytte avkom mot transplacental infeksjon forårsaket av svin parvovirus.

Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - immunologicals for aves - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).

Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - griser - for aktiv immunisering av griser fra 7 ukers alder og framover for å forhindre dødelighet og redusere infeksjon og sykdom forårsaket av klassisk svinepestvirus (csfv). onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.